TrialJournal for immunotherapy of cancer2023

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.

Jason A Chesney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.